title: The ability of selected pyridinium salts to increase the cytotoxic activity of vincristine but not doxorubicin towards sensitive and multidrug resistant promyelocytic leukaemia HL60 cells.
abstract: The aim of this study was to examine the effect of selected pyridinium salts, 1-methyl-3-nitropyridine chloride (MNP(+)Cl(-)) and 3,3,6,6,10-pentamethyl-3,4,6,7-tetrahydro-[1,8(2H,5H)-dion]acridine chloride (MDION(+)Cl(-)), on the activity of doxorubicin (DOX) and vincristine (VINC) towards human promyelocytic leukaemia HL60 cells as well as its multidrug resistant (MDR) sublines exhibiting two different phenotypes of MDR related to the overexpression of P-glycoprotein (HL60/VINC) or MRP1 (HL60/DOX). MNP and MDION salts were much less cytotoxic themselves (about 100-fold and 2000-fold compared with DOX and VINC, respectively) against HL60 cells but, in contrast to DOX and VINC, they conserved an important cytotoxic activity towards resistant HL60/VINC and HL60/DOX cells (resistance factor, RF = 2-4.5). It was shown that MNP(+)Cl(-) and MDION(+)Cl(-) increased the cytotoxicity of non-bioreductive antitumour agent VINC towards human promyelocytic leukaemia HL60 cells and its resistant sublines HL60/VINC and HL60/DOX. However, in the case of DOX the decrease in its cytotoxic activity towards all studied cell lines was observed in the presence of MNP(+)Cl(-) and MDION(+)Cl(-). Presented data suggest that the bioreductive drug DOX, in contrast to VINC, could compete with pyridinium salts (MNP(+)Cl(-) and MDION(+)Cl(-)) for NADPH-dependent oxidoreductases and for undergoing cellular reductive activation. This could explain the inefficiency of these salts to increase the cytotoxic activity of DOX against examined leukaemic HL60 cell line and its MDR sublines, HL60/VINC and HL60/DOX.
authors.affiliation: Department of Biochemistry, University of Szczecin, 3c Felczaka St, 71-412 Szczecin, Poland.
authors.forename: Agnieszka
authors.initials: A
authors.lastname: Maruszewska
authors.forename: Dorota
authors.initials: D
authors.lastname: Kostrzewa-Nowak
authors.forename: Jan
authors.initials: J
authors.lastname: Adamus
authors.forename: Katarzyna
authors.initials: K
authors.lastname: Czupryńska
authors.forename: Dominika
authors.initials: D
authors.lastname: Maryniak
authors.forename: Jerzy
authors.initials: J
authors.lastname: Gebicki
authors.forename: Jolanta
authors.initials: J
authors.lastname: Tarasiuk
mesh_terms: D000166:Acridines / Q000494:pharmacology*; D000903:Antibiotics, Antineoplastic / Q000494:pharmacology*; D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology*; D049109:Cell Proliferation / Q000187:drug effects; D004317:Doxorubicin / Q000494:pharmacology*; D018432:Drug Resistance, Multiple; D019008:Drug Resistance, Neoplasm; D018922:HL-60 Cells; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy; D011726:Pyridinium Compounds / Q000494:pharmacology*; D014750:Vincristine / Q000494:pharmacology*
chemical_list: C488480:1-methyl-3-nitropyridinium; C531414:3,3,6,6,10-pentamethyl-3,4,6,7-tetrahydro-(1,8(2H,5H)-dion)acridine chloride; D000166:Acridines; D000903:Antibiotics, Antineoplastic; D000972:Antineoplastic Agents, Phytogenic; D011726:Pyridinium Compounds; D014750:Vincristine; D004317:Doxorubicin